ARS Pharmaceuticals (SPRY) Assets (2020 - 2026)

ARS Pharmaceuticals' Assets history runs 7 years deep, the most recent figure standing at $287.6 million for Q1 2026.

• In Q1 2026, Assets fell 12.14% year-over-year to $287.6 million; the TTM figure through Mar 2026 stood at $287.6 million (down 12.14% YoY), while the FY2025 annual figure was $327.7 million, down 6.69% from the prior year.
• Assets came in at $287.6 million for Q1 2026 at ARS Pharmaceuticals, down from $327.7 million in the prior quarter.
• In the past five years, Assets ranged from a high of $372.8 million in Q3 2025 to a low of $217.6 million in Q3 2024.
• A 5-year average of $283.4 million and a median of $281.4 million in 2022 frame the typical range for Assets.
• On a YoY basis, Assets climbed as much as 358.02% in 2022 and fell as far as 23.12% in 2022.
• ARS Pharmaceuticals' Assets stood at $281.4 million in 2022, then declined by 17.14% to $233.2 million in 2023, then surged by 50.59% to $351.2 million in 2024, then decreased by 6.69% to $327.7 million in 2025, then fell by 12.23% to $287.6 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $287.6 million, $327.7 million, and $372.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison